Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus) confirmed by laboratory testing
• People whose cancer is at an advanced stage — specifically Stage III with some cancer remaining after surgery, or Stage IV (note: some Stage III patients with no remaining cancer after surgery may also be considered after discussion with the principal investigator)
• People whose endometrial cancer has come back after adjuvant (follow-up) treatment
• People who have had, or are planning to have, surgery to remove the cancer either before or during treatment
• People whose cancer shows specific features on testing — either a marker called MMR-D (mismatch repair deficient) on a tissue test, or MSI-H (microsatellite instability-high) on any commercially available test
• People who have had brain metastases (cancer that has spread to the brain) that have been treated, and whose follow-up brain scans show the cancer there is not getting worse
• People whose treating doctor considers them suitable for standard chemotherapy combined with an immune checkpoint inhibitor drug, with no medical reasons preventing this
• People aged 18 or older
• People who are not currently pregnant and not breastfeeding
• People who have previously received radiation therapy for endometrial cancer (including pelvic radiation, extended field radiation, brachytherapy, or palliative radiation) may be eligible
• People who have previously received hormonal therapy for endometrial cancer may be eligible
• A small number of patients (up to 10) who have already started standard treatment may be eligible to enroll, provided there is no sign their cancer is getting worse at the time of enrollment (confirm with trial site)

Who may not be able to join:

• People who have previously been treated with certain immunotherapy drugs known as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, or similar agents — except for the small group of up to 10 patients specifically allowed to enroll after already starting standard treatment, as described above (confirm with trial site)
• People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.